



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |  |
|---|-----------|--|
| <b>(51) International Patent Classification <sup>6</sup>:</b><br><b>A23L 1/305, 1/30</b>  | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 99/49741</b><br><b>(43) International Publication Date:</b> 7 October 1999 (07.10.99)  |
| <b>(21) International Application Number:</b> PCT/EP99/01274<br><b>(22) International Filing Date:</b> 22 February 1999 (22.02.99)<br><br><b>(30) Priority Data:</b><br>98201016.7      31 March 1998 (31.03.98)      EP<br><br><b>(71) Applicant (for all designated States except US):</b> SOCIETE DES PRODUITS NESTLE S.A. [CH/CH]; P.O. Box 353, CH-1800 Vevey (CH).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> BOZA, Julio [ES/CH]; 2, chemin de la Colline, CH-1093 La Conversion-Lutry (CH). BALLEVRE, Olivier [FR/CH]; 16B, route de Cojonnex, CH-1000 Lausanne 25 (CH). FINOT, Paul-André [FR/CH]; 12, chemin Emile Javelle, CH-1800 Vevey (CH).<br><br><b>(74) Common Representative:</b> SOCIETE DES PRODUITS NESTLE S.A.; McConnell, Bruce, P.O. Box 353, CH-1800 Vevey (CH). |           | <b>(81) Designated States:</b> AU, BR, CA, CN, HU, ID, IL, IN, JP, KR, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> METHOD FOR PROVIDING GLUTAMINE   |           |  |
| <b>(57) Abstract</b>  |           |  |
| <p>A method of providing glutamine to a patient. A nutritional composition which includes whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source is enterally administered to the patient. The whey protein may be a hydrolyzed whey protein. The patient may be a stressed patient, pre-term baby, or athlete.</p>   |           |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    | Republic of Korea                        | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakstan                                | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

### Method For Providing Glutamine

This invention relates to a method for providing glutamine to a human or animal; for example to maintain or increase plasma glutamine levels. The invention also relates to a method for the treatment of humans and animals requiring supplemental glutamine and to a method of increasing glutamine body stores in humans and animals.

The amino acid glutamine has many important functions in the body. For example, glutamine acts as the primary vehicle for transfer of amino nitrogen from skeletal muscle to visceral organs, as a fuel for the rapidly dividing cells of the gastrointestinal tract and immune system, and as a substrate that permits the kidneys to excrete acid loads and protect the body against acidosis. Further, there is increasing evidence that glutamine is essential to the proper functioning of host defence mechanisms and wound healing.

Despite these functions, glutamine is traditionally classified as non-essential amino acid. The reason is that the body is generally able to synthesise sufficient glutamine for its needs from glutamate and glutamic acid. Also, glutamine is the most abundant amino acid in the blood and free amino acid pool of the body. However, this is only true in periods of good health and does not apply to pre-term babies. During periods of illness, the metabolic rate of glutamine increases and the body is not able to synthesise sufficient glutamine to meet its needs. This is particularly true during episodes of stress such as sepsis, injury, burns, inflammation, diarrhoea and surgery. During episodes of stress, there is a marked increase in glutamine consumption by the gastrointestinal tract, immune cells, inflammatory tissue and the kidney. This consumption may far outstrip the endogenous rate of synthesis of glutamine. As the deficiency becomes manifest, tissue function alters, morphological changes may be observed, and a negative nitrogen balance arises. Similarly, pre-term babies have a lower rate of glutamine synthesis; often insufficient for needs. Further, it is found that athletes, after intense exercise, have reduced levels of glutamine in their plasma.

The administration of glutamine supplemented diets to pre-term babies, during periods of stress, or to athletes has resulted in improvement of the person's condition. For example, glutamine supplemented diets have been shown to regenerate muco-proteins and intestinal epithelium, support gut barrier function, shorten hospital stay, improve immune function, and enhance patient survival (Stehle *et al*: 1989; *Lancet*, 1:231-3; Hammerqvist *et al*: 1989; *Ann*.

-2-

*Surg.*; 209:455-461; Li *et al.*; 1995; *J. Parenter. Enteral Nutr.*, 18, 303-307 and Gianotti *et al.*; 1995; *J. Parenter. Enteral Nutr.*, 19, 69-74). Therefore glutamine is now considered to be a conditionally essential amino acid for critically ill and other stressed patients (Lacey *et al.*; 1990; *Nutrition Review*, 48:297-309).

5 The additional need for glutamine during periods of stress must come from an exogenous source such as diet. However the supplementation of nutritional formulas with glutamine has traditionally not been performed because glutamine has long been considered to be a non-essential amino acid. Also glutamine is only slightly soluble in water and, more importantly, is relatively unstable in  
10 solution. To overcome the stability problem, it has been proposed to supplement powdered formulas with L-glutamine. These formulas are then reconstituted immediately prior to administration. However, for enteral formulas, this approach has not proved to be particularly successful since glutamine in its free form may be converted to pyroglutamate by stomach acids prior to absorption.  
15 Also, health care professionals prefer ready-to-consume liquid formulas as opposed to powdered formulas.

Another method of supplementing diet with glutamine has centred on the use of gluten or gluten hydrolysates as a protein source for nutritional compositions. Gluten is particularly rich in glutamine and is hence a good source  
20 of glutamine. Also, the use of gluten or a gluten hydrolysate offers the advantage of providing the glutamine in a form which is stable and relatively soluble. However gluten is potentially allergenic and this has severely limited its use in nutritional formulas. This problem may be ameliorated to some extent by using a gluten hydrolysate instead of gluten and a nutritional composition based on  
25 gluten hydrolysate are commercially available under the trade names Nutricomp® Immun, Reconvan® and Glutasorb®. However, although the risk from allergenic reaction is much reduced, it has not been removed entirely.

A yet further approach has been to supplement nutritional formulas with synthetic dipeptides such as L-alanyl-L-glutamine or L-glycyl-L-glutamine.  
30 These dipeptides are stable in solution and have been shown to be an effective form of glutamine supplementation. However, synthetic peptides of this nature may significantly increase the cost of the nutritional formulas.

Therefore there is a need for an acceptable method of providing glutamine to a patient in need thereof.

35 Accordingly, in one aspect, this invention provides a method of providing glutamine to a mammal, the method comprising enterally administering to the

mammal a nutritional composition which includes whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source.

It has been surprisingly discovered that the administration of nutritional compositions which contain whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source increases plasma glutamine levels in humans or animals. This is despite the fact that whey protein contains relatively low amounts of glutamine. Further, nutritional compositions which contain whey protein as a protein source provide glutamine levels much higher than those provided by nutritional compositions containing free amino acids as protein source.

Preferably the patient, human or animal is a stressed patient, pre-term baby, or athlete. Examples of stressed patients are patients who are critically ill, or who are suffering from sepsis, injury, burns, or inflammation, or patients recovering from surgery.

In another aspect, this invention provides a method of increasing the muscular glutamine levels of a mammal, the method comprising enterally administering to the mammal an effective amount of a nutritional composition which includes whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source.

In a further aspect, this invention provides a method of improving glutamine status of mammals suffering from injured, diseased or under-developed intestines or to maintain the physiological functions of the intestine, the method comprising enterally administering to the mammal an effective amount of a nutritional composition which includes whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source.

The mammal may be a pre-term infant.

Embodiments of the invention are now described by way of example only. The invention is based on the finding that enterally administering a nutritional composition which includes whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source results in high plasma glutamine levels. This makes the composition extremely useful for nutritionally managing glutamine levels in mammals.

The whey protein in the protein source may be may be in the form of intact protein or may be hydrolyzed protein, or mixtures of intact and hydrolyzed protein. The protein source may, if desired, further include amounts of other

suitable types of protein. For example, the protein source may further include minor amounts of casein protein, soy protein, rice protein, pea protein, carob protein, oat protein, caseino-glyco-macropeptide or mixtures of these proteins. Further, if desired, the protein source may further include amounts of free amino acids. The other suitable types of protein preferably comprise less than about 20% by weight of the protein source; more preferably less than about 10% by weight. It is also possible to provide a protein source which simulates the amino acid profile of whey protein. For example, the protein source may comprise about 80% to about 90% by weight of casein, about 0.5 to about 2% by weight of isoleucine, about 2% to about 8% by weight of leucine, about 1% to about 5% by weight of cysteine, and about 1% to about 5% by weight of lysine.

Preferably however, the protein source comprises a whey protein hydrolysate; either based upon sweet whey or acid whey. Whey protein hydrolysates are particularly suitable for patients suffering from compromised gastro-intestinal functions, malabsorption or intolerance. The whey protein hydrolysates may be produced using procedures which are well known in the art. Alternatively, nutritional compositions which contain whey protein hydrolysates may be obtained commercially. For example, clinical nutritional compositions containing whey hydrolysates are commercially available from Nestlé Nutrition Company under the trade mark PEPTAMEN®, or Nutrition Medical, Inc under the trade mark PROPEPTIDES®. Similarly, infant nutritional compositions containing whey hydrolysates are commercially available from Nestlé Alete GmbH under the trade mark ALFARE®.

For infant applications, the whey protein hydrolysate preferably additionally contains the free amino acids arginine, tyrosine and histidine.

For adult applications, whey protein hydrolysates which have a degree of hydrolysis of about 10% to about 20% are particularly preferred. In this specification, the term "degree of hydrolysis" (DH) means the percentage of nitrogen in the form of amino nitrogen as compared to total nitrogen. It is a measure of the extent to which the protein has been hydrolyzed. Whey protein hydrolysates having a degree of hydrolysis of about 10% to about 20% contain less than about 5% of free amino acids, about 15% to about 55% of peptides having a molecular weight of less than 1000 Da, about 20% to about 55% of peptides having a molecular weight of 1000 Da to 5000 Da, and about 15% to about 35% of peptides having a molecular weight of greater than 5000 Da.

For adult applications, the protein source preferably provides about 10% to about 20% of the energy of the nutritional composition. For example, the protein source may provide about 15% to about 18% of the energy of the nutritional composition. For infant applications, the protein source preferably provides about 50% to about 30% by dry weight of the nutritional composition. For example, full term infant formulas, the protein source may provide about 8% to about 20% by dry weight of the nutritional composition. Further, for pre-term infant formulas, the protein source may provide about 15% to about 25% by dry weight of the nutritional composition.

The nutritional composition may also include a carbohydrate source. For adult applications, the carbohydrate source preferably provides about 35% to about 65% of the energy of the nutritional composition; especially 40% to 60% of the energy of the nutritional composition. For example, the carbohydrate source may provide about 51% of the energy of the composition. For infant applications, the carbohydrate source preferably provides about 35% to about 70% by dry weight of the nutritional composition; more preferably about 45% to about 65% by dry weight. Several carbohydrates may be used including maltodextrin, corn starch, modified starch, lactose, or sucrose, or mixtures thereof. Preferably the composition is free from lactose.

The nutritional composition may further include a lipid source. For adult applications, the lipid source preferably provides about 20% to about 50% of the energy of the nutritional composition; especially 25% to about 40% of the energy of the nutritional composition. For example, the lipid source may provide about 33% of the energy of the nutritional composition. For infant applications, the lipid source preferably provides about 15% to about 35% by dry weight of the nutritional composition; especially 20% to about 30% by dry weight of the nutritional composition. For example, the lipid source may provide about 26% by dry weight of the nutritional composition.

The lipid source may comprise a mixture of medium chain triglycerides (MCT) and long chain triglycerides (LCT). If MCT's are included, the lipid source preferably contains at least about 30% to about 80% by weight of medium chain triglycerides. For example, medium chain triglycerides may make up about 70% by weight of the lipid source. Suitable sources of long chain triglycerides are sunflower oil, safflower oil, rapeseed oil, palm olein, soy oil, milk fat, corn oil and soy lecithin. Fractionated coconut oils are a suitable source of medium chain triglycerides.

The lipid profile of the nutritional composition may be designed to have a polyunsaturated fatty acid omega-6 (n-6) to omega-3 (n-3) ratio of about 1:1 to about 12:1. For example, for adult applications, the n-6 to n-3 fatty acid ratio may be about 6:1 to about 9:1. For infant applications, the n-6 to n-3 fatty acid ratio may be about 9:1 to about 11:1. Also, for infant applications, the lipid source may include long chain, polyunsaturated fatty acids such as arachidonic acid and docosahexaenoic acid.

The nutritional composition preferably includes a complete vitamin and mineral profile. For example, sufficient vitamins and minerals may be provided to supply about 50% to about 250% of the recommended daily allowance of the vitamins and minerals per 1000 calories of the nutritional composition.

For adult applications, the nutritional composition preferably has an energy content of about 800 kcal/l to about 1200 kcal/l; for example an energy content of about 1000 kcal/l. For infant applications, the nutritional composition preferably has an energy content of about 600 kcal/l to about 1000 kcal/l; for example an energy content of about 650 kcal/l to about 850 kcal/l.

The nutritional composition may be in any suitable form. For example, the nutritional composition may be in the form of a soluble powder, a liquid concentrate, or a ready-to-drink formulation. Alternatively, the nutritional composition may be in solid form; for example in the form of a ready-to-eat bar or breakfast cereal. Ready to drink formulations are particularly preferred. The composition may be fed to a patient via a nasogastric tube, jejunum tube, or by having the patient drink or eat it. Various flavours, fibres, sweeteners, and other additives may also be present.

The nutritional composition may be produced as is conventional; for example, the nutritional composition may be prepared by blending together the protein source, the carbohydrate source, and the lipid source. If used, the emulsifiers may be included in the blend. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the lipid source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture. The temperature of the water is conveniently about 50°C to about 80°C to aid dispersal of the ingredients. Commercially available liquefiers may be used to form the liquid mixture.

The liquid mixture may then be thermally treated to reduce bacterial loads. For example, the liquid mixture may be rapidly heated to a temperature in the



range of about 80°C to about 110°C for about 5 seconds to about 5 minutes. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.

5 The liquid mixture may then be cooled to about 60°C to about 85°C; for example by flash cooling. The liquid mixture is then homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage. The homogenised mixture may then be further cooled to add any heat sensitive components; such as vitamins and minerals. The pH and solids content of the homogenised mixture is conveniently  
10 standardised at this point.

If it is desired to produce a powdered nutritional composition, the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder. The powder should have a moisture content of less than about 5% by weight. If it is desired to produce a  
15 liquid nutritional composition, the homogenised mixture is preferably aseptically filled into suitable containers. Aseptic filling of the containers may be carried out by pre-heating the homogenised mixture (for example to about 75 to 85°C) and then injecting steam into the homogenised mixture to raise the temperature to about 140 to 160°C; for example at about 150°C. The homogenised mixture may  
20 then be cooled, for example by flash cooling, to a temperature of about 75 to 85°C. The homogenised mixture may then be homogenised, further cooled to about room temperature and filled into containers. Suitable apparatus for carrying out aseptic filling of this nature is commercially available.

The nutritional composition may be used as a nutritional support, especially  
25 for providing nutrition and glutamine to animals and humans. In particular, the nutrition composition may be used to provide nutrition and glutamine to stressed patients; for example for patients who are critically ill, or who are suffering from sepsis, injury, burns, or inflammation, or patients recovering from surgery. Further, the nutritional composition may be used to provide glutamine to patients  
30 suffering from injured or diseased intestines or to maintain the physiological functions of the intestine. Moreover, the nutritional composition may be used to raise plasma glutamine levels in humans and animals.

The nutritional composition may also be used to provide glutamine to athletes after intense exercise or to pre-term babies.

It is to be understood that, although the nutritional composition is intended primarily for patients who require supplemental glutamine, it may also be used as a source of nutrition for people who are not suffering from any illness or condition.

The nutritional composition may form the sole source of nutrition or form a supplement to other nutritional sources; including parenterally administered nutrition.

The amount of the nutritional composition required to be fed to a patient will vary depending upon factors such as the patient's condition, the patient's body weight, the age of the patient, and whether the nutritional composition is the sole source of nutrition. However the required amount may be readily set by a medical practitioner. In general, sufficient of the nutritional composition is administered to provide the patient with about 1 g protein to about 4.0 g protein per kg of body weight per day. For example, an adult, critically ill patient may be administered about 1.5 g protein to about 2.0 g protein per kg of body weight per day, a pre-term infant may be administered about 2.0 g protein to about 4.0 g protein per kg of body weight per day, and a infant may be administered about 2.0 g protein to about 3.0 g protein per kg of body weight per day. Further, for stressed patients, sufficient of the nutritional composition is preferably administered to provide the patient with about 10g to about 25 g of glutamine per day. The nutritional composition may be taken in multiple doses, for example 2 to 5 times, to make up the required daily amount or may taken in a single dose. Alternatively, the nutritional composition may be fed to the patient continuously.

Specific examples of the invention are now described for further illustration.

#### Example 1

An isotonic liquid diet which is suitable for raising plasma glutamine levels in a patient is obtained from Nestlé Clinical Nutrition. The diet is commercialised under the trademark PEPTAMEN®. The diet has the following components:

| Nutrient   | Amount per 1000 ml |
|--|--------------------|
| Protein (hydrolyzed sweet whey)  | 40 g               |
| Carbohydrate (maltodextrin, corn starch)   | 127                |
| Lipid (medium chain triglycerides, sunflower oil, soy lecithin)  | 39                 |
| Vitamin A  | 4000 IU            |
| Vitamin D  | 280 IU             |
| Vitamin E  | 28 IU              |
| Vitamin K  | 80 µg              |
| Vitamin C  | 140 mg             |
| Thiamin  | 2 mg               |
| Riboflavin   | 2.4 mg             |
| Niacin   | 28 mg              |
| Vitamin B <sub>6</sub>   | 4 mg               |
| Folic acid   | 540 µg             |
| Pantothenic acid   | 14 mg              |
| Vitamin B <sub>12</sub>  | 8 µg               |
| Biotin   | 400 µg             |
| Choline  | 450 mg             |
| Taurine  | 80 mg              |
| L-carnitine  | 80 mg              |
| Minerals<br>Calcium, Phosphorus,<br>Magnesium, Zinc, Iron, Copper,<br>Manganese, Iodine, Sodium,<br>Potassium, Chloride, Chromium,<br>Molybdenum, Selenium |                    |

The diet has an energy density of 1000 kcal/l and the protein provides 16% of energy, the carbohydrate provides 51% of energy, and the lipid provides 33% of energy. Glutamine provides about 6.2 % by weight of the protein source.

## 5 Example 2

### i) Test Diets:-

The following diets are used in the test:

| Diet    | Composition   | Protein Source           | Glutamine Content (g/100g) |
|---------|---|--------------------------|----------------------------|
| 1       | 95% composition of example 1 and 5% cellulose   | Hydrolyzed whey          | 6.2                        |
| 2       | 95% PROPEPTIDES product and 5% cellulose  | Hydrolyzed whey          | 5.42                       |
| A       | 95% VIVONEX PLUS product and 5% cellulose   | Free amino acids         | 21.63                      |
| B       | 95% REABILAN product and 5% cellulose   | Hydrolyzed casein & whey | 8.09                       |
| Control | soy protein isolate, sucrose, glucose, cellulose, corn starch, corn oil and vitamins and minerals | Soy                      | 8.99                       |

The VIVONEX PLUS product is a product obtained from Sandoz Nutrition AG. The REABILAN product is a product obtained from Nestlé Clinical Nutrition.

### ii) Test Analytical Procedures

Plasma amino acids are analyzed by de-proteinising 200 µl of plasma using 20 µl of a solution containing sulfosalicylic acid (400 mg/ml) and vitamin C (60 mg/ml). The mixture is centrifuged at 10'000g for 3 minutes. D-glucosaminic acid and S-(2-aminomethyl)-L-cysteine.HCl are added to the supernatant as

internal standards and the supernatant is frozen at  $-80^{\circ}\text{C}$  until analyzed. A Beckman 6300 amino acid analyzer is used for the analysis. To avoid glutamine degradation, all samples are kept at  $10^{\circ}\text{C}$  before analysis. Amino acid concentrations are calculated for individual peak areas, external standards and the internal standards.

Muscle glutamine is analyzed by mixing 100 mg of muscle with an ice cold solution of trichloroacetic acid (10% w/v) and homogenising the mixture at 10'000 rpm for 1 minute. The mixture is then centrifuged at 10'000 g for 10 minutes at  $4^{\circ}\text{C}$ . D-glucosaminic acid is added to the supernatant as internal standard and the supernatant is frozen at  $-80^{\circ}\text{C}$  until analyzed. A Beckman 6300 amino acid analyzer is used for the analysis. To avoid glutamine degradation, all samples are kept at  $10^{\circ}\text{C}$  before analysis. Amino acid concentrations are calculated for individual peak areas, external standards and the internal standards.

### iii) Test Procedure

Fifty six male Wistar rats, each weighing about 200g, are used. The rats are held in separate cages at  $23^{\circ}\text{C}$ . A 12 hour dark cycle is imposed. The rats have free access to water and the Control diet.

The rats are maintained on the Control diet for 3 days. On the fourth day, the amount of the Control diet for each rat is restricted to 80% of its consumption on the previous three days. The Control diet is fed to the rats once a day. On the seventh day, the rats are placed in metabolic cages and randomised by weight into 7 groups of 8 rats. One group of rats, the control group, is maintained on the Control diet. The rats in the remaining groups are then starved for 72 hours. All rats have free access to water.

At the end of the starvation period, a 1 ml blood sample is taken from the eye of each rat of one group under anaesthesia; the control starved group. The blood sample is then analyzed for plasma amino acids as described above. The rats of this group are then sacrificed and the muscle tibialis of rat are removed and stored at  $-80^{\circ}\text{C}$  until analyzed for muscle glutamine as described above.

The remaining tests rats are placed into new metabolic cages and are again randomised by weight into five groups of 8.

The five groups are then each fed an experimental diet; the diets differing from group to group. The diets are as follows:

-12-

| Group          | Diet    |
|----------------|---------|
| Control Re-fed | Control |
| 1              | 1       |
| 2              | 2       |
| A              | A       |
| B              | B       |

The rats are fed the diets for 3 days. At the end of the three days, a 1 ml blood sample is taken from the eye of each rat of one group under anaesthesia. Plasma samples are then analyzed for plasma amino acid concentrations as described above. The rats are then sacrificed and the muscle tibialis of rats are removed. The muscle is analyzed for muscle glutamine as described above.

#### iv) Test Results

The plasma glutamine concentrations are as follows:

| Group           | Diet    | Glutamine Intake ( $\mu\text{mol/l}$ ) | Plasma glutamine ( $\mu\text{mol/l}$ ) | Muscle glutamine ( $\mu\text{mol/g}$ ) |
|-----------------|---------|--|--|--|
| Control         | Control | 733                                    | 829.1                                  | 4                                      |
| Control starved | Control | -                                      | 758.6                                  | 2.7                                    |
| Control re-fed  | Control | 734                                    | 742.5                                  | 3.6                                    |
| 1               | 1       | 392                                    | 1025.6                                 | 5.3                                    |
| 2               | 1       | 336                                    | 1031.1                                 | 4.9                                    |
| A               | A       | 1501                                   | 738.7                                  | 3.3                                    |
| B               | B       | 424                                    | 881.7                                  | 3.9                                    |

The results indicate that the rats fed diets 1 and 2, the whey protein based diets, have plasma glutamine concentrations of at least 25% higher than the other rats. This is despite the fact that the rats fed diets 1 and 2 received less glutamine in the diet; and significantly less than the free amino acid diet A. Similarly, the results indicate that the rats fed diets 1 and 2 have higher muscle glutamine concentrations; significantly higher than the control rats in the case of diet 1.

-13-

Further, the rats fed diets 1 and 2 recovered better after starvation in terms of weight gain, food conversion efficiency, retained nitrogen to ingested nitrogen, retained nitrogen to absorbed nitrogen and protein efficiency ratio.

Claims

- 5 1. The use of whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source in the preparation of a enterally administrable nutritional composition for increasing plasma glutamine concentration in a stressed mammal.
- 10 2. The use of whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source in the preparation of a enterally administrable nutritional composition for increasing muscle glutamine concentrations in a mammal.
- 15 3. The use of whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source in the preparation of a enterally administrable nutritional composition for providing glutamine to a mammal suffering from injured, diseased or under-developed intestines.
- 20 4. The use according to claim 3 in which the mammal is a pre-term infant having an under-developed intestine.
- 25 5. The use according to claim 4 in which the whey protein is hydrolyzed and the protein source further comprises arginine, tyrosine and histidine.
- 30 6. The use according to claim 1 in which the whey protein is hydrolyzed whey protein.
- 35 7. The use according to claim 6 in which the hydrolyzed whey protein contains less than about 5% by weight of free amino acids, about 15% to about 55% by weight of peptides having a molecular weight of less than 1000 Da, about 20% to about 55% by weight of peptides having a molecular weight of 1000 Da to 5000 Da, and about 15% to about 35% by weight of peptides having a molecular weight of greater than 5000 Da.
8. The use according to any of claims 1 to 3 in which the protein source provides about 10% to about 20% of the energy of the nutritional composition.



-15-

Sub  
A1

9. The use according to any of claims 1 to 3 in which the nutritional composition further includes a lipid source which provides about 20% to about 50% of the energy of the nutritional composition, the lipid source comprising a mixture of medium chain and long chain fatty acids.

5

add  
A2

10. The use according to any of claims 1 to 3 in which the nutritional composition further includes a carbohydrate source which provides about 35% to about 65% of the energy of the nutritional composition.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 99/01274

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A23L1/305 A23L1/30

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | DE 297 11 429 U (A.REICHENAUER-FEIL)<br>6 November 1997<br>see page 2, paragraph 1<br>see page 3, paragraph 3<br>see page 6; table<br>see claims 1-4,9                             | 1,2                   |
| X          | EP 0 022 019 A (INSTITUT NATIONAL DE LA<br>RECHERCHE AGRONOMIQUE(INRA))<br>7 January 1981<br>see page 22, line 31 - page 23, line 34<br>see examples 2,3,5,6<br>see claims 1,15-20 | 1-7                   |
| A          |  | 8-10                  |
|            | -/--   |                       |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 May 1999

Date of mailing of the international search report

04/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van Moer, A

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/01274

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| X        | <p>DATABASE WPI<br/> Section Ch, Week 9317<br/> Derwent Publications Ltd., London, GB;<br/> Class B04, AN 93-136778<br/> XP002103442<br/> -&amp; JP 05 065295 A (SNOW BRAND MILK PROD CO LTD), 19 March 1993<br/> see abstract</p> <p style="text-align: center;">---</p> | 1,3                   |
| A        | <p>EP 0 705 542 A (SANDOZ NUTRITION)<br/> 10 April 1996<br/> see page 2, line 55-58<br/> see page 8, line 5-11<br/> see claims 1-6,8</p> <p style="text-align: center;">---</p>   | 1-10                  |
| A        | <p>EP 0 418 593 A (MILUPA) 27 March 1991<br/> see page 3, line 3-51<br/> see page 4, line 18-21<br/> see page 4, line 43-46<br/> see page 5, line 21-29<br/> see page 5, line 55-58<br/> see claims; example 1</p> <p style="text-align: center;">---</p>                 | 1-10                  |
| A        | <p>PATENT ABSTRACTS OF JAPAN<br/> vol. 096, no. 002, 29 February 1996<br/> &amp; JP 07 255398 A (SNOW BRAND MILK PROD CO LTD), 9 October 1995<br/> see abstract</p> <p style="text-align: center;">-----</p>  | 1                     |

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| DE 29711429                               | U | 06-11-1997          | DE 19717195 A              | 29-10-1998          |
| EP 22019                                  | A | 07-01-1981          | FR 2459620 A               | 16-01-1981          |
|   |   |                     | AR 231376 A                | 30-11-1984          |
|   |   |                     | AU 535601 A                | 29-03-1984          |
|   |   |                     | AU 5966780 A               | 08-01-1981          |
|   |   |                     | BR 8003974 A               | 13-01-1981          |
|   |   |                     | CA 1150564 A               | 26-07-1983          |
|   |   |                     | DK 273480 A                | 27-12-1980          |
|   |   |                     | FI 802011 A,B,             | 27-12-1980          |
|   |   |                     | JP 1666661 C               | 29-05-1992          |
|   |   |                     | JP 56032488 A              | 01-04-1981          |
|   |   |                     | JP 62061039 B              | 18-12-1987          |
|   |   |                     | US 4427658 A               | 24-01-1984          |
|   |   |                     | ZA 8003749 A               | 24-06-1981          |
| EP 705542                                 | A | 10-04-1996          | US 5719133 A               | 17-02-1998          |
|   |   |                     | AT 161397 T                | 15-01-1998          |
|   |   |                     | CA 2158635 A,C             | 22-03-1996          |
|   |   |                     | DE 69501306 D              | 05-02-1998          |
|   |   |                     | DE 69501306 T              | 18-06-1998          |
|   |   |                     | ES 2111384 T               | 01-03-1998          |
|   |   |                     | GR 3026072 T               | 29-05-1998          |
|   |   |                     | HK 1005768 A               | 22-01-1999          |
|   |   |                     | SG 33502 A                 | 18-10-1996          |
|   |   |                     | SI 705542 T                | 30-04-1998          |
|   |   |                     | US 5719134 A               | 17-02-1998          |
| EP 418593                                 | A | 27-03-1991          | AT 96621 T                 | 15-11-1993          |
|   |   |                     | DD 297304 A                | 09-01-1992          |
|   |   |                     | DE 59003330 D              | 09-12-1993          |
|   |   |                     | DK 418593 T                | 13-12-1993          |
|   |   |                     | ES 2062231 T               | 16-12-1994          |
|   |   |                     | GR 3026131 T               | 29-05-1998          |
|   |   |                     | PT 95114 A,B               | 18-04-1991          |
|   |   |                     | TR 24775 A                 | 01-05-1992          |

62

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

26 JUIN 2000

PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT  
(PCT Rule 71.1)

To:

McConnell Bruce  
SOCIETE DES PRODUITS NESTLE S.A.  
55, avenue Nestlé  
CH-1800 Vevey  
SUISSE

Date of mailing  
(day/month/year) 23.06.2000

Applicant's or agent's file reference

NO 6303/WO

## IMPORTANT NOTIFICATION

International application No.  
PCT/EP99/01274

International filing date (day/month/year)  
22/02/1999

Priority date (day/month/year)  
31/03/1998

Applicant

SOCIETE DES PRODUITS NESTLE S.A. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

## 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Tantum, P

Tel. +49 89 2399-8143



## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

|  |   |   |
|--|---|---|
| Applicant's or agent's file reference<br><b>NO 6303/WO</b>                                       | <b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) |   |
| International application No.<br><b>PCT/EP99/01274</b>   | International filing date (day/month/year)<br><b>22/02/1999</b>   | Priority date (day/month/year)<br><b>31/03/1998</b> |
| International Patent Classification (IPC) or national classification and IPC<br><b>A23L1/305</b> |   |   |
| Applicant<br><b>SOCIETE DES PRODUITS NESTLE S.A. et al.</b>                                      |   |   |

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 8 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

|   |  |
|---|--|
| Date of submission of the demand<br><br><b>26/10/1999</b>   | Date of completion of this report<br><br><b>23.06.2000</b>                         |
| Name and mailing address of the international preliminary examining authority:<br><br> European Patent Office<br>D-80298 Munich<br>Tel. +49 89 2399 - 0 Tx: 523656 epmu d<br>Fax: +49 89 2399 - 4465 | Authorized officer<br><br><b>Heirbaut, M</b><br><br>Telephone No. +49 89 2399 8642 |



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP99/01274

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

**Description, pages:**

1-13 as originally filed

**Claims, No.:**

1-10 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

|                               |      |             |
|-------------------------------|------|-------------|
| Novelty (N)                   | Yes: | Claims      |
|                               | No:  | Claims 1-10 |
| Inventive step (IS)           | Yes: | Claims      |
|                               | No:  | Claims 1-10 |
| Industrial applicability (IA) | Yes: | Claims 1-10 |
|                               | No:  | Claims      |

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP99/01274

---

**2. Citations and explanations**

**see separate sheet**

**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**



## V

1. Reference is made to the following documents (D):

D1: DE-U-29 711 429

D2: EP-A-0 022 019

D3: DATABASE WPI Section Ch, Week 9317 Derwent Publications Ltd., London, GB; Class B04, AN 93-136778 XP002103442 & JP-A-05 065 295

D4: EP-A-0 418 593

D5: PATENT ABSTRACTS OF JAPAN vol. 096, no. 002, 29 February 1996 & JP-A-07 255 398

2. The subject-matter of present independent claim 1 (use) does not meet the requirements of Article 33(2) PCT concerning novelty in the light of any of the prior art documents D1 or D2, which describe the combination of features disclosed in said claim.

Document D1 describes a drink preparation comprising 5-30 wt% of whey protein as a protein with a high content of the amino acids glutamine, asparagine, leucine, isoleucine and arginine, to be used before, during or after **physical stress** (see in particular claim 4; table on page 6 of D1). Hence, said preparation is used by **stressed mammals**. Said amino acids have an anti-tiredness and performance-maintaining effect (see in particular page 3, paragraph 3 of D1). As the drink preparation has a high content of glutamine, it **increases plasma glutamine concentrations in mammals**.

Document D2 describes a hydrolysate of whey proteins that can be assimilated directly through the intestinal mucosa (see in particular claim 1; page 7, lines 5-9; examples 2-3, 5-6 of D2). Any type of whey can be used as a starting material (see in particular page 14, lines 8-10 of D2). The hydrolysate is used in therapeutical nutrition, and as a medicament in the treatment of patients (being **stressed mammals**) with gastro-duodenical ulcers, partly removed intestines or ileitis (see in particular page 23, lines 9-14 of D2). As the whey protein hydrolysate comprises glutamine and it is used for nutritional purposes, it **increases plasma glutamine concentrations in mammals**.

3. The subject-matter of present independent claim 2 (use) does not meet the requirements of Article 33(2) PCT concerning novelty in the light of any of the prior art documents D1-D5, which describe the combination of features disclosed in said claim.

Document D1 describes a drink preparation comprising 5-30 wt% of whey protein as a protein with a high content of the amino acids glutamine, asparagine, leucine, isoleucine and arginine, to be used before, during or after **physical stress** (see in particular claim 4; table on page 6 of D1). Said amino acids have an anti-tiredness and performance-maintaining effect (see in particular page 3, paragraph 3 of D1). As the drink preparation has a high content of glutamine, **it increases muscle glutamine concentrations in mammals.**

Document D2 describes a hydrolysate of whey proteins that can be assimilated directly through the intestinal mucosa (see in particular claim 1; page 7, lines 5-9; examples 2-3, 5-6 of D2). Any type of whey can be used as a starting material. (see in particular page 14, lines 8-10 of D2). The hydrolysate is used in therapeutical nutrition, and as a medicament in the treatment of patients with gastro-duodenical ulcers, partly removed intestines or ileitis (see in particular page 23, lines 9-14 of D2). As the whey protein hydrolysate comprises glutamine and is used for nutritional purposes, **it increases muscle glutamine concentrations.**

Document D3 describes a hydrolysate of whey protein concentrate (WPC), which is used as **a drug or a food additive** (see abstract of D3). As the whey protein concentrate comprises glutamine and is used for nutritional purposes, **it increases muscle glutamine concentrations**

Document D4 describes protein-, peptide- and amino acid mixes with optimised amino acid composition, comprising glutamine, used for the preparation of **infant and baby nutritional compositions** (see in particular page 2, lines 1-3; claims 1-3 of D4). Instead of intact proteins protein hydrolysates such as whey protein hydrolysates can be used (see in particular page 5, lines 55-57 of D4). As the whey protein hydrolysate comprises glutamine and is used for nutritional purposes, **it increases muscle glutamine concentrations.**

Document D5 describes a nutrient composition, capable of stably feeding a large amount of glutamine, containing a whey protein and a hydrolysate of a whey protein (see abstract of D5). As the whey protein (hydrolysate) comprises glutamine and is used for nutritional purposes, **it increases muscle glutamine concentrations.**

As present independent claim 2 relates to the use of a **nutritional** composition, rather than a composition for treating stressed mammals or mammals suffering from a disorder, the teaching of prior art documents D1-D5 is novelty-destroying for the subject-matter of said claim, even though the effect of increasing muscle glutamine concentrations is not explicitly described in said documents.

4. The subject-matter of present independent claim 3 (use) does not meet the requirements of Article 33(2) PCT concerning novelty in the light of the prior art document D2, which describes the combination of features disclosed in said claim.

Document D2 describes a hydrolysate of whey proteins that can be assimilated directly through the intestinal mucosa (see in particular claim 1; page 7, lines 5-9; examples 2-3, 5-6 of D2). Any type of whey can be used as a starting material (see in particular page 14, lines 8-10 of D2). The hydrolysate, which comprises glutamine, is used in therapeutical nutrition, and as a medicament in the treatment of patients with **gastro-duodenical ulcers, partly removed intestines or ileitis**, being mammals suffering from injured, diseased or under-developed intestines (see in particular page 23, lines 9-14 of D2).

5. Concerning the question whether the subject-matter of present independent claims 1-3 meets the requirements of inventive step (Article 33(3) PCT), it is stressed that cited documents D1-D5 are also related to nutritional compositions comprising whey protein or whey protein hydrolysates.
6. Dependent claims 4-10 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of novelty and/or inventive step (Articles 33(2) and 33(3) PCT).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP99/01274

7. For the assessment of the present claims 1 and 3 on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.
8. If amendments are carried out, the Applicant is requested to point out where in the application as originally filed the basis for such amendments can be found (Article 34(2)(b) PCT).
9. Any information the applicant may wish to submit concerning the subject-matter of the invention, for example further details of its advantages or of the problem it solves, and for which there is no basis in the application as filed, should be confined to the letter of reply rather than be incorporated into the application (Article 34(2)(b) PCT).
10. When filing amended claims, the Applicant should at the same time bring the description into conformity with the amended claims. Care should be taken during revision, especially of the introductory portion and any statements of problem or advantage, not to add subject-matter which extends beyond the content of the application as originally filed (Article 34(2)(b) PCT).

## **VII**

1. The present application does not meet the requirements of Rule 67.1 (iv) PCT, as the passages on page 1, lines 3-7; page 2, line 35 to page 3, line 3; page 3, lines 16-26 relate to methods of treatment of the human or animal body by therapy.
2. The present application does not meet the requirements of Rule 10.1 PCT, as the units of measure "kcal" used throughout the description have not been expressed additionally in terms of the metric system.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP99/01274

3. The present application does not meet the requirements of Rule 5.1 (a)(ii) PCT, as the prior art documents D1-D5 have not been cited in the description (see also PCT Guidelines II, 4.4).

## **VIII**

1. The present application does not meet the requirements of clarity (Article 6 PCT).
  - 1.1. The feature "a protein mixture which simulates the amino acid profile of whey protein" in present independent claims 1-3 is vague. This objection could be overcome e.g. by addition of the features disclosed on page 4, lines 8-11 of the present description.
  - 1.2. The expression "about" used in present claims 7-10 and throughout the present description is vague. This objection could be overcome by deletion of said expression.